Insulin production today primarily utilizes recombinant DNA technology, where bacteria such as Escherichia coli are genetically modified to express the human insulin gene. This method allows for the large-scale production of insulin, ensuring a consistent and reliable supply for diabetes management. The process involves inserting the human insulin gene into bacterial plasmids, which are then cultivated to produce insulin. This biotechnological advancement has significantly improved the availability and affordability of insulin compared to previous extraction methods from animal sources.
PREREQUISITESStudents studying biotechnology, healthcare professionals involved in diabetes treatment, and anyone interested in the biopharmaceutical industry.